Merck
CN
所有图片(2)

文件

安全信息

C4461

Sigma-Aldrich

硫酸粘杆菌素 硫酸盐

≥19,000 IU/mg

登录查看公司和协议定价

别名:
多粘菌素E
CAS号:
EC 号:
MDL编号:
eCl@ss:
34050906
NACRES:
NA.85

形式

powder

质量水平

比活

≥19,000 IU/mg

抗生素抗菌谱

Gram-negative bacteria

作用机制

cell membrane | interferes

储存温度

2-8°C

InChI

1S/C53H100N16O13.H2O4S/c1-9-30(6)12-10-11-13-41(72)60-33(14-20-54)48(77)69-43(32(8)71)53(82)65-36(17-23-57)45(74)64-38-19-25-59-52(81)42(31(7)70)68-49(78)37(18-24-58)62-44(73)34(15-21-55)63-50(79)39(26-28(2)3)67-51(80)40(27-29(4)5)66-46(75)35(16-22-56)61-47(38)76;1-5(2,3)4/h28-40,42-43,70-71H,9-27,54-58H2,1-8H3,(H,59,81)(H,60,72)(H,61,76)(H,62,73)(H,63,79)(H,64,74)(H,65,82)(H,66,75)(H,67,80)(H,68,78)(H,69,77);(H2,1,2,3,4)/t30?,31-,32-,33+,34+,35+,36+,37+,38+,39+,40-,42+,43+;/m1./s1

InChI key

ZJIWRHLZXQPFAD-LRYSGCCDSA-N

正在寻找类似产品? Visit 产品对比指南

相关类别

一般描述

化学结构:肽

应用

硫酸粘杆菌素被用于透化细菌细胞膜以及研究甘露糖抗性血凝和某些生物体(如鲍曼不动杆菌 A. baumannii )的抗生素耐药性。 它已被用于研究大鼠肾脏hephrotoxicity毒性 ,以及对铜绿假单胞菌的MIC值、时间杀灭动力学和抗生素后效应(PAE)

生化/生理作用

作用机制:与革兰氏阴性菌细胞质膜上的脂质结合并破坏细胞壁完整性。
抗菌谱: 革兰氏阴性菌。
作用机制:与革兰氏阴性菌细胞质膜上的脂质结合并破坏细胞壁完整性。
抗菌谱: 革兰氏阴性菌。硫酸粘杆菌素的肾重吸收被认为可能涉及到有机阳离子转运蛋白和肽转运蛋白,并且该过程对pH敏感

分析说明

易溶于水,几乎不溶于丙酮和乙醇(96%)

其他说明

保持容器密闭,置于干燥通风处。

相关产品

产品编号
说明
价格

象形图

Skull and crossbones

警示用语:

Danger

危险声明

预防措施声明

危险分类

Acute Tox. 3 Oral

储存分类代码

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

法规信息

监管及禁止进口产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

为方便起见,与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码?

在网站页面上,产品编号会附带包装尺寸/数量一起显示(例如:T1503-25G)。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题?欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ (Lot或Batch)字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等,请输入去除前两位字母的批号:09019TO。

  • 如果您查询到的批号含有填充代码(例如05427ES-021),请输入去除填充代码-021的批号:05427ES。

  • 如果您查询到的批号含有填充代码(例如 STBB0728K9),请输入去除填充代码K9的批号:STBB0728。

未找到您寻找的产品?

部分情况下,可能未在线提供COA。如果搜索不到COA,可在线索取。

索取COA

Anna Ebbensgaard et al.
Frontiers in microbiology, 9, 2153-2153 (2018-09-25)
Bacterial resistance to classical antibiotics is emerging worldwide. The number of infections caused by multidrug resistant bacteria is increasing and becoming a serious threat for human health globally. In particular, Gram-negative pathogens including multidrug resistant Escherichia coli are of serious
Candace M Marr et al.
Frontiers in microbiology, 11, 595798-595798 (2020-11-17)
Acinetobacter baumannii is a problematic pathogen due to its common expression of extensive drug resistance (XDR) and ability to survive in the healthcare environment. These characteristics are mediated, in part, by the signal transduction system BfmR/BfmS. We previously demonstrated, in
José María Saugar et al.
Antimicrobial agents and chemotherapy, 50(4), 1251-1256 (2006-03-30)
Acinetobacter baumannii has successfully developed resistance against all common antibiotics, including colistin (polymyxin E), the last universally active drug against this pathogen. The possible widespread distribution of colistin-resistant A. baumannii strains may create an alarming clinical situation. In a previous
Xingchen Bian et al.
International journal of antimicrobial agents, 57(2), 106271-106271 (2020-12-23)
Polymyxin-based combination therapy is often used to treat carbapenem-resistant Acinetobacter baumannii (A. baumannii) infections. Although sulbactam is intrinsically active against A. baumannii, few studies have investigated colistin/sulbactam combinations against carbapenem-resistant A. baumannii. Whole genome sequencing was undertaken on eight carbapenem-resistant (colistin-susceptible)
Deepesh Nagarajan et al.
Science advances, 5(7), eaax1946-eaax1946 (2019-07-30)
Drug resistance is a public health concern that threatens to undermine decades of medical progress. ESKAPE pathogens cause most nosocomial infections, and are frequently resistant to carbapenem antibiotics, usually leaving tigecycline and colistin as the last treatment options. However, increasing

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门